Pfizer (PFE) Tops Q3 EPS by 44c, Beats on Revenue; Offers FY24 Guidance

Pfizer (NYSE: PFE) reported Q3 EPS of $1.06, $0.44 better than the analyst estimate of $0.62. Revenue for the quarter came in at $17.7 billion versus the consensus estimate of $14.92 billion.

GUIDANCE:

Pfizer sees FY2024 EPS of $2.75-$2.95, versus the consensus of $2.65. Pfizer sees FY2024 revenue of $61-64 billion, versus the consensus of $61.2 billion.

For earnings history and earnings-related data on Pfizer (PFE) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• PreveCeutical closes second tranche of private placement for $245,000
• Lennar Corp. (LEN) Misses Q2 EPS by 1c